Laurie Glimcher (Franck Fife/AFP via Getty Images)

Biden's choice for FDA may be a wild card as top can­di­date says she's not in the run­ning

Pres­i­dent Biden told re­porters yes­ter­day that he’s close to nom­i­nat­ing some­one to be the next FDA com­mis­sion­er, but it still re­mains un­clear who he might se­lect.

With a lit­tle more than a month to make his nom­i­na­tion, ex­perts and Politi­co point­ed yes­ter­day to Dana-Far­ber Can­cer In­sti­tute CEO Lau­rie Glim­ch­er as a top can­di­date, giv­en her lead­er­ship po­si­tion and drug de­vel­op­ment ex­pe­ri­ence.

But Glim­ch­er, an im­mu­nol­o­gist by train­ing who al­so serves on Glax­o­SmithK­line’s board, told End­points News via email on Thurs­day: “I am com­mit­ted to Dana-Far­ber Can­cer in­sti­tute and our on­go­ing progress against can­cer, and I am not a can­di­date to be the next com­mis­sion­er of the FDA.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.